We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

79 hedge funds and large institutions have $250M invested in UroGen Pharma in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more call options, than puts

Call options by funds: $4.89M | Put options by funds: $3.55M

3% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.33% less ownership

Funds ownership: 67.6% → 66.27% (-1.3%)

8% less funds holding

Funds holding: 86 → 79 (-7)

47% less capital invested

Capital invested by funds: $473M → $250M (-$223M)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
79
Holders Change
-7
Holders Change %
-8.14%
% of All Funds
1.74%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
4
Increased
31
Reduced
30
Closed
11
Calls
$4.89M
Puts
$3.55M
Net Calls
+$1.34M
Net Calls Change
+$1.85M

Top Buyers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
+$13.8M
2
Artisan Partners
Artisan Partners
Wisconsin
+$8.28M
3
N
Nuveen
North Carolina
+$7.32M
4
PC
Pier Capital
Connecticut
+$4.06M
5
HCM
Horton Capital Management
Pennsylvania
+$3.86M

Top Sellers

Rank Fund Capital Flow
1
HCM
Highline Capital Management
New York
-$16.9M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.41M
3
WCM
Wildcat Capital Management
New York
-$6.91M
4
MIH
Meitav Investment House
Israel
-$6.53M
5
BBA
Baker Bros. Advisors
New York
-$4.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
26
Vanguard Group
Pennsylvania
$1.45M +$17.2K +636 +0.8%
Citadel Advisors
27
Citadel Advisors
Florida
$1.22M -$146K -5,405 -7%
Victory Capital Management
28
Victory Capital Management
Texas
$1.09M +$718K +26,584 +77%
SAM
29
Shikiar Asset Management
New York
$937K -$391K -14,475 -22%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$860K -$1.05K -39 -0.1%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$839K +$9.02K +334 +0.7%
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$747K +$162K +5,998 +17%
Charles Schwab
33
Charles Schwab
California
$724K +$5.67K +210 +0.5%
AA
34
ALPS Advisors
Colorado
$680K -$120K -4,451 -10%
CBA
35
Coastal Bridge Advisors
Connecticut
$660K +$468K +17,308 +88%
Swiss National Bank
36
Swiss National Bank
Switzerland
$615K +$13.5K +500 +1%
MIH
37
Meitav Investment House
Israel
$544K -$6.53M -241,657 -89%
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$543K +$62.8K +2,323 +8%
PPA
39
Parametric Portfolio Associates
Washington
$442K +$102K +3,792 +18%
PAI
40
Palo Alto Investors
California
$437K +$662K +24,500 New
EMG
41
ETF Managers Group
New Jersey
$428K +$56.6K +2,096 +10%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$420K +$3.86K +143 +0.6%
AS
43
Altshuler Shaham
Israel
$419K -$72.2K -2,671 -10%
Group One Trading
44
Group One Trading
Illinois
$391K -$166K -6,154 -22%
AllianceBernstein
45
AllianceBernstein
Tennessee
$391K – – –
UBS AM
46
UBS AM
Illinois
$389K +$146K +5,400 +33%
AIM
47
ARK Investment Management
Florida
$300K +$21.5K +796 +5%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$291K – – –
Jane Street
49
Jane Street
New York
$258K -$466K -17,250 -54%
BHB
50
Bank Hapoalim BM
Israel
$258K -$69.5K -2,574 -15%
1
2
3 4

URGN Hedge Fund Activity: Q1 2020 in Review

79 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2020, worth a combined $250M — down 47% from $473M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of URGN and 4 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 31 added.

The largest buyer was Clal Insurance, adding an estimated $13.8M. The largest seller was Highline Capital Management, cutting an estimated $16.9M.

  • 79 institutional investors held UroGen Pharma (URGN) as of Q1 2020, down from 86 in Q4 2019.
  • Funds reported $250M of UroGen Pharma stock for Q1 2020, down 47% quarter-over-quarter.
  • 4 funds opened new UroGen Pharma positions in Q1 2020 and 11 closed out, a net change of -7 holders.
  • The largest UroGen Pharma buyer in Q1 2020 was Clal Insurance, an estimated $13.8M added.
  • The largest UroGen Pharma seller in Q1 2020 was Highline Capital Management, an estimated $16.9M sold.

Based on aggregated 13F filings for Q1 2020.